Creyos Unveils Promising Findings at Alzheimer's Conference
Findings from distinguished research institutions highlight the capability of Creyos to identify early cognitive risks and validate its digital testing methods. These insights contribute to our understanding of cognitive resilience as well.
With its established use in over 400 peer-reviewed studies, Creyos is at the forefront of brain health research globally. This digital assessment platform continues to elevate standards, providing reliable, comprehensive evaluations of cognitive abilities.
Recently, Creyos was featured in notable presentations at a leading Alzheimer's Association International Conference. This platform is particularly important for researchers aiming to enhance early detection of cognitive health issues and strategies to protect brain function as individuals age.
Developed over three decades of neuroscience research and validated through extensive studies, Creyos provides rapid and accurate assessments across key cognitive domains: memory, attention, reasoning, and executive function. Its applications extend to many prominent research institutions investigating profound questions in neuroscience.
Adrian Owen, Professor of Cognitive Neuroscience at the University of Western Ontario and Chief Scientific Officer at Creyos, stated, "Creyos originated from a need within science to rigorously and effectively assess cognitive function. It has been embraced by researchers worldwide and contributes significantly to the field of cognitive health research. Observing its role in advancing scientific inquiries is incredibly rewarding."
The conference highlighted three pivotal studies:
1. Early Screening Through Digital Tasks
Using data from over 4,000 older adults, researchers utilized machine learning to pinpoint the two most predictive Creyos tasks for detecting cognitive impairment related to age. A screener that included attention and working memory tasks demonstrated remarkable accuracy, aligning with clinical diagnoses of Alzheimer's disease. These results showcase Creyos as an effective alternative to conventional dementia screening methods.
2. Genetics, Risk, and Online Testing in a PISA Study
This extensive study, part of the Prospective Imaging Study of Aging, validated the Creyos platform for online cognitive testing among adults aged 42-75. Researchers compared self-administered assessments with results from traditional testing and MRI-derived measures. The findings indicated strong correlations between online and in-person outcomes, providing key insights into the potential of digital methods for cost-effective early detection in Alzheimer's research.
3. Cognitive Resilience in Aging Adults
Addressing why some individuals retain cognitive function despite age-related challenges, this study evaluated over 3,300 individuals. Creyos was used to highlight the Grammatical Reasoning task as a significant marker of cognitive resilience, correlating strong performance with less dependence on episodic memory and greater resilience after trauma. This research suggests reasoning skills as a potential protective factor against cognitive decline.
The studies affirm Creyos' reliability in rigorous scientific inquiry. The platform's integration into research emphasizes the growing role cognitive data plays in fostering early detection and improved patient care protocols. Healthcare professionals across various fields, including primary care and behavioral health, utilize Creyos for screening cognitive health and guiding treatment strategies.
Creyos demonstrates a commitment to enhancing brain health assessments, with nearly 20 million evaluations executed and more than 10,000 providers using it actively. Its innovative approach is transforming the interface between research data and practical healthcare applications.
About Creyos
Creyos, previously known as Cambridge Brain Sciences, is a groundbreaking healthcare technology firm committed to optimizing the assessment and management of brain health. The platform offers a range of online tasks, digital behavioral health screeners, and condition-specific assessments that yield actionable insights, encouraging proactive intervention and informed clinical decisions across cognitive and behavioral health issues. Supported by extensive research and a database with more than 85,000 participants, the FDA-registered Creyos platform is a scientifically recognized tool for brain health measurement. To learn more about Creyos, visit www.creyos.com.
Media Contact
[email protected]
Frequently Asked Questions
What is Creyos?
Creyos is a digital platform used to assess and manage brain health through online cognitive assessments.
How does Creyos contribute to Alzheimer's research?
Creyos aids researchers by providing reliable assessments for early detection and understanding cognitive resilience in aging populations.
What are the main advantages of using Creyos?
Creyos offers fast, scalable, and accurate cognitive measurements, supporting both clinical practice and extensive research initiatives.
Who uses Creyos?
Healthcare providers, researchers, and clinicians across various fields utilize Creyos to evaluate cognitive health and inform care decisions.
What kind of studies have featured Creyos?
Creyos has been featured in numerous peer-reviewed studies focusing on cognitive function, resilience, genetics, and online testing efficacy.
